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Enterobacter aerogenes and E. cloacae have been reported as important opportunistic
and multiresistant bacterial pathogens for humans during the last three decades in
hospital wards. These Gram-negative bacteria have been largely described during
several outbreaks of hospital-acquired infections in Europe and particularly in France.
The dissemination of Enterobacter sp. is associated with the presence of redundant
regulatory cascades that efficiently control the membrane permeability ensuring the
bacterial protection and the expression of detoxifying enzymes involved in antibiotic
degradation/inactivation. In addition, these bacterial species are able to acquire
numerous genetic mobile elements that strongly contribute to antibiotic resistance.
Moreover, this particular fitness help them to colonize several environments and
hosts and rapidly and efficiently adapt their metabolism and physiology to external
conditions and environmental stresses. Enterobacter is a versatile bacterium able to
promptly respond to the antibiotic treatment in the colonized patient. The balance of
the prevalence, E. aerogenes versus E. cloacae, in the reported hospital infections
during the last period, questions about the horizontal transmission of mobile elements
containing antibiotic resistance genes, e.g., the efficacy of the exchange of resistance
genes Klebsiella pneumoniae to Enterobacter sp. It is also important to mention the
possible role of antibiotic use in the treatment of bacterial infectious diseases in this E.
aerogenes/E. cloacae evolution.
Keywords: Enterobacter aerogenes, Enterobacter cloacae, membrane and transporters, regulation, resistance
mechanisms
Introduction
Enterobacter is a genus of a common Gram-negative, facultative anaerobic, rod-shaped, non-
spore-forming bacteria belonging to the family Enterobacteriaceae. Two of its well- known species,
Enterobacter aerogenes and E. cloacae have taken on clinical signiﬁcance as opportunistic bacteria
and have emerged as nosocomial pathogens from intensive care patients pathogenic, especially to
those who are on mechanical ventilation (Mezzatesta et al., 2012).
Enterobacter aerogenes was originally named Aerobacter aerogenes, and was later included in
the genus Enterobacter in 1960. In 1971, this species was proposed to be renamed Klebsiella
mobilis due to its motility conferred by peritrichous ﬂagella and its genetic relatedness to Klebsiella
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genus. It is interesting to note that phenotypic dissimilarities
between E. aerogenes and the genusKlebsiella include not only the
motility but also the presence of ornithine decarboxylase (ODC)
activity and the lack of urease activity in E. aerogenes (Farmer
et al., 1985). However, recently, the whole genome sequenc-
ing of a multidrug-resistant (MDR) clinical isolate, (including
colistin) suggested a possible reclassiﬁcation of the species in
the genus Klebsiella, under the name K. aeromobilis (Diene
et al., 2013). E. aerogenes particular phenotype can be attributed
to the horizontal acquisition of additional genes from other
Enterobacteriaceae species and mobile elements that rapidly inte-
grated and translated as easily as its own ancestral heritage (Diene
et al., 2013). For example, the ﬂagellar genes and its assembly sys-
tem have been acquired in bloc from the Serratia genus. Plasmid
conjugation is a chimera of transposons and genetic elements
(conjugation, integration) of various bacterial origins. E. aero-
genes also contains eight rRNA operons and 87 tRNA associated
with the ability to translate imported genes that use diﬀerent
codons, improving its ability to use its integrated foreign genes.
E. aerogenes has been involved in signiﬁcant European outbreak
between 1993 and 2003 and is considered as the paradigm of
opportunistic bacteria.
Species of the E. cloacae complex are widely encountered
in nature, but they are also pathogens: E. cloacae and E.
hormaechei are most frequently isolated from human clini-
cal specimens. Thus, E. cloacae is among the most common
Enterobacter sp. causing only nosocomial infections in the
last decade and a lot has been published on the antibiotic-
resistance features of these microorganisms. Despite the rele-
vance of E. cloacae as a nosocomial pathogen, the pathogenic
mechanisms and factors contributing in the disease associ-
ated with the E. cloacae complex are not understood yet; this
could be due to the scarcity and the dispersion of informa-
tion available. Its ability to form bioﬁlms and to secrete vari-
ous cytotoxins (enterotoxins, hemolysins, pore-forming toxins)
are important for its pathogenicity (Mezzatesta et al., 2012).
Some genotypes and species, have previously exhibited some
associations with clinical specimens, in particular urines and
sputum, when clonal outbreaks with members of the E. cloa-
cae complex were rare (Izdebski et al., 2014). Interestingly,
due to the diﬀusion of most frequent extended spectrum
β-lactamases (ESBL) and carbapenemases in this species, E. cloa-
cae has now become the third broad spectrum Enterobacteriaceae
species involved in nosocomial infections after Escherichia coli
and K. pneumoniae (Potron et al., 2013; Jarlier and INVS,
2014).
Epidemiology and Infections
Enterobacter aerogenes is isolated as human clinical speci-
mens from respiratory, urinary, blood, or gastrointestinal tract
(Langley et al., 2001). Epidemiology of this species has been
particular in Europe: it has regularly been involved in nosoco-
mial infections outbreaks since 1993, particularly in the Western
Europe (Georghiou et al., 1995; Grattard et al., 1995; Allerberger
et al., 1996; Arpin et al., 1996; Davin-Regli et al., 1996; De Gheldre
et al., 1997; Jalaluddin et al., 1998). Until, 2003, E. aerogenes was
considered as an important emerging MDR pathogen, particu-
larly in ICUs (Bosi et al., 1999; Chevalier et al., 2008; Figure 1).
The situation in 1990s in Europe pointed to the dispersion
of an epidemic clone and, since then, it has been extensively
detected in European hospitals and health care facilities. The
event ﬁtted in with the international spread of the ESBL TEM-24
(blaTEM−24) harbored by an epidemic plasmid (Bosi et al., 1999).
The prevalence of Enterobacter sp. infections in clinical wards
has also increased due to the introduction of extended-spectrum
cephalosporins and carbapenems in the antibiotic therapy (Arpin
et al., 1996; Anastay et al., 2013). The consequence of this antibio-
therapy is the emergence of “pan-drug E. aerogenes isolates”
resistant to last-line antibiotics such as carbapenems and also to
colistin, for which no therapeutic option was available (Chevalier
et al., 1999; Thiolas et al., 2005; Diene et al., 2013). Interestingly,
the role of eﬄux mechanism in E. aerogenes resistance has been
studied within an 8 years of period. This study indicated a
noticeable increase of the prevalence of an eﬄuxmechanism, sus-
ceptible to pump inhibitor, in clinical isolates collected during
this period (Chevalier et al., 2008). After the emergence of ESBL
in E. aerogenes and the characterisation of porin mutations in
clinical isolates, this role of eﬄux mechanism highlights a new
step in the adaptative evolution in E. aerogenes (Charrel et al.,
1996; Malléa et al., 1998; Gayet et al., 2003).
Since 2010, E. aerogenes in France is the ﬁfth highest
Enterobacteriaceae and the seventh highest Gram-negative
Bacillus responsible for notorious nosocomial infections
(Carbonne et al., 2013; Figure 2). Despite its intrinsic resistance
to ampicillin and constant expression of ESBL that is associated
with other resistance mechanisms contributing to MDR pheno-
type, its prevalence has signiﬁcantly dropped (reduction factor
of 20) in France (Anastay et al., 2013; Jarlier and INVS, 2014).
Its position was displaced in the context of hospital acquired
infections, because of the dramatic rise of the E. coli pandemic
clone O25:H4-ST131 along with K. pneumoniae and E. cloacae,
ESBL, and/or carbapenemase producing strains. Although, E.
FIGURE 1 | Schematic illustration of the timing of Enterobacter
species during the emergence of resistance outbreaks in France
hospitals (Arpin et al., 1996; Bornet et al., 2000; Chevalier et al., 2008;
Lavigne et al., 2012; Mezzatesta et al., 2012; Anastay et al., 2013;
Robert et al., 2014). ESBLs, extended-spectrum β-lactamases.
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FIGURE 2 | Distribution of the main species of
Enterobacteriaceae-ESBL (n for 10,000 patient days): evolution
2002–2013 from the French national coordination of MDRB
surveillance (Carbonne et al., 2013; Jarlier and INVS, 2014). ENT AER,
Enterobacter aerogenes; ENT CLO, E. cloacae; ESC COL, E. coli; KLE PNE,
Klebsiella pneumoniae; TOT ENB, Total Enterobacteriaceae; ESBLs,
extended-spectrum β-lactamases.
aerogenes causes septic shock more readily in patients thus
leading to a higher mortality rate (Song et al., 2010; Lavigne
et al., 2012), E. cloacae is now the most frequently observed
clinical isolate among Enterobacter sp. It can be associated with
the dissemination of actual epidemic plasmids bearing most
prevalent resistant genes and expressing new β-lactamases or
carbapenemases (Figure 2).
Enterobacter cloacae is ubiquitous in terrestrial and aquatic
environments (water, sewage, soil, and food). The species occurs
as commensal microﬂora in the intestinal tracts of humans
and animals and is also pathogens in plants and insects.
This diversity of habitats is mirrored by the genetic vari-
ety of E. cloacae (Mezzatesta et al., 2012). Recently, MLST
and PFGE epidemiological methods data revealed world cir-
culation of several epidemic clonal complexes (Izdebski et al.,
2014).
It is also a well-known nosocomial pathogen contributing
to bacteremia, endocarditis, septic arthritis, osteomyelitis, and
skin/soft tissue infections, and lower respiratory tract- urinary
tract and intra-abdominal infections (Fata et al., 1996). E. cloa-
cae tends to contaminate various medical, intravenous, and other
hospital devices (Dugleux et al., 1991). Nosocomial outbreaks
have also been associated with the colonization of certain surgical
equipment and operative cleaning solutions (Wang et al., 2000).
Since a decade, E. cloacae has been repeatedly reported as a noso-
comial pathogen in neonatal units and several outbreaks of infec-
tion have been reported (Fernandez-Baca et al., 2001; Pestourie
et al., 2014). Today, variability among strains are less frequent
and outbreaks due to clonal E. cloacae hyper-producing AmpC
β-lactamase and ESBL carrier isolates are described from neonate
specimens, adults urines/feces samples or from environmental
samples (Pestourie et al., 2014).
Enterobacter cloacae has an intrinsic resistance to ampi-
cillin, amoxicillin, ﬁrst-generation cephalosporins, and cefoxitin
owing to the production of constitutive AmpC β-lactamase.
It exhibits a high frequency of enzymatic resistance to broad-
spectrum cephalosporins. Resistance of Enterobacter sp. to
third-generation cephalosporins is most typically caused by
overproduction of AmpC β-lactamases, and thus treatment
with third-generation cephalosporins may select for AmpC-
overproducing mutants. AmpC overproduction is due to the
derepression of a chromosomal gene or by the acquisition of
a transferable ampC gene from plasmids or other mobile ele-
ments. The AmpC plasmid-mediated resistance is distinguished
from chromosomal enzyme production because they are not
inducible. However they represent a problem due to its increas-
ing prevalence among clinical isolates. The enzyme confers a
resistance to third-generation cephalosporins and ureido- and
carboxy-penicillins and is not inhibited by common inhibitors
of β-lactamases. Fourth-generation cephalosporins retain rea-
sonable activity against derepressed strains, but if strains are
also ESBL producers, they become resistant to this antibiotic
class. The prevalence of ESBL and CTX-M producers repre-
sented approximatively 5% of the isolates in the recent studies
and ESBLs are most often plasmid-mediated. These characteris-
tics, associated with the frequent endogenous intestinal carriage
of E. cloacae, may result in abnormally high levels in the bow-
els of hospitalized patients, especially those who have received
cephalosporins (Potron et al., 2013).
Enzymatic Barrier and Antibiotic
Resistance
The production of β-lactamases is the prominent mechanism
responsible for β-lactam resistance in most of these species. E.
aerogenes strains have a broad ability to develop antibiotics resis-
tance mechanisms (Miro et al., 1995). They naturally express a
chromosomal AmpC β-lactamase type cephalosporinase at low
level (group 1 Bush) that induces resistance to ﬁrst-generation
cephalosporins (Freney et al., 1988). Chromosomal acquired
β-lactams resistance mechanisms induce the overproduction
of chromosomal AmpC cephalosporinase: this results from an
induction during a third-generation cephalosporin treatment or
by a mutation in the AmpR repressor, and generates a resistance
to almost all β-lactams (Preston et al., 2000). Moreover, it has
been described that E. aerogenes strains harboring cephalospori-
nase AmpC gene, integrated the gene of chromosomal origin
(blaCMY-10) on a large plasmid (130 kb), contributing to a
systematic gene transmission even in the absence of antibiotic
pressure (Lee et al., 2003).
In 1993 appeared the ﬁrst cases of nosocomial infections
caused by strains with resistance to common β-lactam antibi-
otics due to ESBL (Pitout et al., 1998). The ESBL TEM- 24
associated to E. aerogenes clonal dissemination in France was
constantly reported (Neuwirth et al., 1996; Bosi et al., 1999;
Bertrand et al., 2003). Other ESBLs of TEM type or CTX-M
type (ex CTX-M-2) are often identiﬁed but TEM-24 remains
associated with preferential conjugative plasmid of this species
(Arpin et al., 2002; Dumarche et al., 2002; Biendo et al., 2008;
Kanamori et al., 2012). Due to the well-described modiﬁcation
of porins expression and recent dissemination of plasmid bearing
carbapenemases, a number of imipenem-resistant clinical strains
have come up (Miro et al., 1995; Bornet et al., 2000; Biendo
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et al., 2008; Lavigne et al., 2012). Carbapenemases of NDM and
VIM types are now, as anticipated, reported in E. aerogenes in
India and those for the serine protease group as KPC or class
D β-lactamases possessing carbapenemase properties as OXA-48
types are described in Europe/Asia (Khajuria et al., 2014; Torres
et al., 2014).
Similarly to E. aerogenes, E. cloacae is also naturally resistant to
ampicillin, amoxicillin–clavulanic acid, cephalothin, and cefox-
itin by low production of the natural inducible cephalosporinase
of Bush group 1 (class C). They are capable of overproduc-
ing AmpC β-lactamases by blocking the repression of a chro-
mosomal gene or by the acquisition of a transferable ampC
gene on plasmids conferring the resistance to third-generation
cephalosporins (Nauciel et al., 1985; Zaher and Cimolai, 1997).
Cefepime alone can keep its activity (Sanders and Sanders, 1997).
Clinical AmpC resistance represents 50% of the isolates and fre-
quently co- exists with the expression of ESBL. In 1989, appeared
the ﬁrst nosocomial isolate cases bearing plasmidic ESBL caus-
ing also resistance to third generation cephalosporins except
cefamycins (De Champs et al., 1989). Together, these enzymes
are responsible for a global resistance to all β-lactams except
carbapenems (Pitout et al., 1997). In the last decade, E. cloa-
cae has emerged as the third most common Enterobacteriaceae
resistant to third generation cephalosporins with enteric E. coli
and K. pneumoniae (Jarlier and INVS, 2014). Imipenem remains
the most eﬀective molecule for treating E. cloacae infections.
Since then, various ESBL of TEM, SHV, and CTX -M types
have been characterized in E. cloacae including resistant TEM
inhibitors or IRT (for inhibitor-resistant TEM; Arpin et al., 2002;
Szabo et al., 2005; Galas et al., 2008). However, among ESBL
producers, some sub-clones are now identiﬁed, associated with
CTX-M-3 and 15 production, when other TEM or SHV (SHV-12
for example) types are also associated with epidemic-episodes-
involved isolates. Diﬀusion of E. cloacae producing CTX-M-15
ESBL is the consequence of the wide dissemination of identical
or related plasmids harboring the CTX-M-15 gene ﬁrstly identi-
ﬁed in the epidemic E. coli clone, and the CTX-M β-lactamases
are now the most prevalent ESBL globally (Hammami et al.,
2012).
In recent years, clinical isolates resistant by producing car-
bapenemases have been identiﬁed (Nordmann et al., 1993; Galani
et al., 2005). In 2010, CDC ﬁrst reported carriage of NDM-1
in E. cloacae from patients who received medical care in India.
Especially in Asia, strains harboring metallo-β-lactamases as IMP
-type enzymes, NDM, GIM, VIM, and serine carbapenemase
type KPC have been described (Huang et al., 2012; Dai et al.,
2013; Hamprecht et al., 2013; Jaskulski et al., 2013). The OXA-
48 type serine carbapenemase is the most prevalent because
its gene is located on a plasmid, associated to the bla-CTX-
M-15 gene coding ESBL, thus explaining its spread and the
associated resistance (Potron et al., 2013; Torres et al., 2014).
A hike in the imipenem resistance rate in E. cloacae, from
0.4 to 8 %, has been observed (Lee et al., 2005; Poirel et al.,
2007; Robert et al., 2014). An epidemic study concerning E.
cloacae blood stream infections indicated a 25% production of
metallo-β-lactamase in corresponding strains (Khajuria et al.,
2014). Thus, the decreased susceptibility to carbapenems in
hospital acquired E. cloacae isolates might arise via stepwise
accumulations of MDR determinants in diﬀerent clones. Today,
E. cloacae is the second Enterobacteriaceae carrying carbapen-
emase and strains co-expressing two carbapenemases has been
reported (Izdebski et al., 2014).
Regarding the aminoglycosides, the major mechanism of
resistance of the Enterobacteriaceae is due to aminoglycoside-
modifying enzymes that are often plasmid-encoded, but it may
also be associated with transposable elements. These enzymes
are assigned to three groups: acetyltransferases (acetylation of
an amino group/AAC), phosphotransferases (phosphorylation
of a hydroxyl group/APH), and adenylyltransferases (adenylyla-
tion of a hydroxyl group/AAD or ANT). Plasmid exchanges and
disseminations of transposons facilitate the rapid acquisition of
resistance phenotypes (Mezzatesta et al., 2012).
The resistant strain varies from 0 to 51% resistance for gen-
tamicin, and 0 to 34% for amikacin (Sanders and Sanders, 1997).
In 2013, an important epidemiological study conﬁrmed that the
aminoglycoside-modifying genes involved in aminoglycoside-
clinical resistance were aac(3)-IIa, aac(6′)-Ib, and ant(2′ ′)-Ia,
genes that confer resistance to tobramycin, gentamicin, and
amikacin (Miró et al., 2013). Strains have frequently more than
one enzyme (Miró et al., 2013). This enzymatic type resistance
is associated in 77% of clinical isolates in China to other plas-
mid genes (armA, rmtB; Huang et al., 2012). Among these,
the aminoglycoside AAC(6′)-Ib is the most common cause of
amikacin resistance among members of the Enterobacteriaceae
family. In a previous study, it was observed that over 40% of the
E. cloacae isolates had the aac(6′)-Ib gene, although many of the
isolates with this gene were susceptible to amikacin and gentam-
icin, which were the most active of all tested drugs (Kim et al.,
2009).
The enzymatic resistance to ﬂuoroquinolones has been
recently described and attributed to a two-point mutation allele
of aac(6′)-Ib [named aac(6′)-Ib-cr], the aminoglycosides resis-
tance enzymatic determinant, which acetylates ciproﬂoxacin and
norﬂoxacin (Huang et al., 2012). A systematic molecular survey
reporting prevalence and characteristics of aac(6′)-Ib-cr in Korea,
characterized a high prevalence of the mechanism (23%) in E.
cloacae (Huang et al., 2012). Dissemination of this new enzymatic
resistance mechanism occurs since the aac(6′)-Ib-cr is highly
associated with blaOXA−1, ISCR1, and class 1 integron. This
supports the previous ﬁnding where aac(6′)-Ib-cr was located
upstream of blaOXA−30 (synonymously called blaOXA−1) in com-
plex class 1 integron, In37 containing ISCR1 (Quiroga et al.,
2007). A genetic linkage between aac(6′)-Ib-cr and blaCTX−M−15
has been demonstrated (Huang et al., 2012).
Membrane Barrier and Antibiotic
Resistance
Porin and Membrane Permeability
Carbapenems are the most powerful agents for the treat-
ment of serious nosocomial infections caused by MDR
Enterobacteriaceae. Due to the imipenem use, it was rapidly
reported a decreased penetration of β-lactams due to a change
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in the expression of porins in E. aerogenes isolates. Charrel et al.
(1996) showed that MDR strains of E. aerogenes exhibited a
characteristic phenotype associated with an altered expression
of porins and then successive studies comforted description of
more frequent MDR strains in treated patients by β-lactams
(Bornet et al., 2000; Fernandez-Cuenca et al., 2006). This mech-
anism of resistance is reversible upon discontinuation of treat-
ment (Bornet et al., 2000) and progressive during treatment.
Among intermediate strains which are susceptible to imipenem
but resistant to ertapenem, there is a loss of porin Omp35
but the expression of porin Omp36 is preserved. When treat-
ment with imipenem continues, the disappearance of two porins
and resistance to all carbapenems is noted (Lavigne et al.,
2013). Recently, a novel mechanism of resistance has been
observed in a clinical strain where the antibiotic cannot be eﬃ-
ciently translocated through a mutated porin (see Mutation and
Antibiotic Resistance). Additionally, imipenem and carbapene-
mase KPC type have been described as responsible for resistance
to carbapenems associated to decrease in membrane permeabil-
ity (Jaskulski et al., 2013). The conductance and selectivity of
these porins, Omp35, and Omp36, correspond to the proper-
ties obtained with OmpC and OmpF of E. coli (Bornet et al.,
2004; James et al., 2009). Moreover, several studies have further
described a decrease in production of these porins in resistant
isolates (Bornet et al., 2000; Yigit et al., 2002; Gayet et al., 2003;
Doumith et al., 2009; Tran et al., 2009). Two major outer mem-
brane porins have been identiﬁed in E. cloacae and studied by
liposome swelling assays (Lee et al., 1992). These porins are
involved in the carbapenem susceptibility (Raimondi et al., 1991;
Lee et al., 1992) and exhibit important cross antigenicity with
the E. aerogenes porins in speciﬁc key parts, e.g., eyelet region,
membrane insertions, subunit connections (Malléa et al., 1995).
In addition, their respective involvement in β-lactam and ﬂuoro-
quinolone uptake has been reported (Chevalier et al., 2000; James
et al., 2009).
Interestingly, the expression of porin in Enterobacteriaceae is
rapidly and notably altered by various stress compounds present
in the external medium (Dupont et al., 2007). During the ﬁrst
hours of incubation in the presence of salicylate, novobiocin, nor-
ﬂoxacin a signiﬁcant increase of OmpX is observed and this over-
expression negatively controls the synthesis of porins (Dupont
et al., 2007).
Efflux and Membrane Permeability
Furthermore, an eﬄux mechanism that is involved in the
expelling of molecules from the bacteria such as ﬂuoro-
quinolones, tetracycline, and chloramphenicol is active in
Enterobacter sp. (Malléa et al., 1998). This mechanism is highly
eﬃcient since the AcrAB–TolC eﬄux pump can eject about
80–90% of the norﬂoxacin during the ﬁrst 10–15 min (Malléa
et al., 1998). Interestingly, this process is energy-dependent and
requires the membrane energy (proton motive force) as exten-
sively described (for a recent review see Nikaido and Pagès, 2012).
Approximately 40% of MDR clinical strains have an active eﬄux
(Chevalier et al., 2008). The EefABC and AcrAB–TolC eﬄux
genes of E. aerogenes have been described and their involvement
in antibiotic exportation has been studied (Pradel and Pagès,
2002; Masi et al., 2005, 2006; Martins et al., 2010). Several studies
on E. cloacae have also reported the presence of eﬄux pumps
belonging to RND and MATE families (Pérez et al., 2007; He
et al., 2011). In addition, the AcrAB–TolC and OqxAB genes
have been characterized in E. cloacae clinical resistant isolates
(Pérez et al., 2007, 2012; Veleba et al., 2013). In E. aerogenes and
E. cloacae, the sequence similarities and biological activity are
particularly high in AcrAB–TolC (Pradel and Pagès, 2002; Pérez
et al., 2007). Moreover, various chemicals such as salicylate, chlo-
ramphenicol, and imipenem are also able to trigger the genetic
cascade controlling the expression of Enterobacter AcrAB–TolC
pump (Davin-Regli et al., 2008). The regulation seems to be asso-
ciated with the internal concentration of chemicals that plays a
key role during the switch on of the cascade that provides the
eﬄux expression (Valade et al., 2013).
MarA acts as a key regulator for the expression of porin
genes and tolC in Enterobacteriaceae (Levy, 2002; Piddock, 2006;
Alekshun and Levy, 2007; Davin-Regli et al., 2008). SoxS is
another key transcriptional regulator that is positively controlled
by oxidative stress and can trigger theMarA expression (Masi and
Pagès, 2013). Some Enterobacteriaceae sp., such as Enterobacter,
Klebsiella, Salmonella, have an additional global regulator, RamA.
It plays a strategic role in controlling both the porins and
the eﬄux expression, either directly or via the MarA cascade.
This coordinated control of inﬂux and eﬄux directly and eﬃ-
ciently governs the intracellular accumulation of antibacterial
agents. Importantly, this internal accumulation of antibacterial
molecules below the threshold corresponding to the MIC can
favor the emergence and acquisition of additional mechanisms
of resistance such as target mutation, production of detoxify-
ing enzymes (e.g., β-lactamases, acetyltransferase, etc), and con-
tributing to the extension ofMDRphenotype (Nikaido and Pagès,
2012; Masi and Pagès, 2013).
Regarding the active structure of eﬄux pumps involved in
E. aerogenes and E. cloacae; we can hypothesize that a com-
mon structural organization is conserved, due to the high
conserved homology between Enterobacter and E. coli. This
structural organization can be similar to the recent descrip-
tion of the AcrAB–TolC complex in E. coli (Du et al.,
2014).
Mutations and Antibiotic Resistance
Regarding the β-lactam antibiotics, the resistance due to tar-
get mutation occurs incidentally in Enterobacter sp. However,
the diverse β-lactamases identiﬁed today is the result of a series
of mutations that have successively appeared in the original
β-lactamases TEM-1/2, SHV-1, OXA-1.
Furthermore, strains in which AmpC cephalosporinase was
derepressed have been aﬀected by mutations aﬀecting AmpR-
promoter recognition site. Mutations that are best known and
studied are those that aﬀect the target of ﬂuoroquinolones
and more recently those responsible for polymyxin resistance.
As a matter of fact, the quinolones were widely prescribed
antimicrobial agents because of their proven safety, high oral
bioavailability, multiple approved indications, and bactericidal
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activity. Consequently, in the microbial population, a variety of
amino acid alterations arose from mutations within quinolone
resistance-determining regions (QRDRs) of cellular target genes
gyrA and parC and conferred high-level resistance. This is one
of the most common resistance mechanisms identiﬁed among
clinical isolates of Enterobacter, despite recent characteriza-
tion of plasmid-mediated quinolone resistance (PMQR) genes
(qnrA, qnrS, aac(6′)-Ib-cr, qepA, and oqxAB; Park et al., 2009;
Kanamori et al., 2012). In E. cloacae the plasmid-borne QnrA
and QnrS resistances inducing protection from the DNA bind-
ing of ﬂuoroquinolones are observed, but such mechanisms
confers low-level resistance when present alone (Corkill et al.,
2005; Poirel et al., 2005; Huang et al., 2012; Kanamori et al.,
2012). However, such PMRQ mechanisms have got an eﬃ-
cient dissemination and are found in over 60% of the strains,
because were found to be co-carried with various ESBLs or
AmpC-type β-lactamases on the same plasmid (Park et al.,
2009; Huang et al., 2012). Finally, associated to active eﬄux,
target mutations are the most eﬃcient resistance mechanisms
resulting in high MICs values, while PMRQ mechanisms confer
only an additive eﬀect on the level of ﬂuoroquinolones resis-
tance.
Finally, pan-drug resistance is not an exceptional phenotype
in E. aerogenes, since resistant strains to all antibiotics, includ-
ing colistin pmrA substitution, were isolated and described to
be associated with colistin resistance (Thiolas et al., 2005; Diene
et al., 2013).
Regarding the permeation pathway, it is important to men-
tion that during the last decade, we observed the emergence
of well-located mutation inside the pore constriction of the
Omp36 (OmpC like porin of E. aerogenes) that generate a strong
resistance against β-lactams (Dé et al., 2001; Thiolas et al.,
2004). This speciﬁc mutation altering the pore characteristics
impairs the diﬀusion of all β-lactams including cephalosporins
and carbapenems, represents the ﬁrst type of an adaptative
mutation of bacterial porin in a resistant clinical isolates of
Enterobacteriaceae (Chevalier et al., 1999; Thiolas et al., 2004).
Interestingly, the intensity of MIC modiﬁcation conferred by
the speciﬁc residues depends on the structure and charge of
the antibiotic molecules. A recent study reports the molec-
ular simulations and dynamics of β-lactams inside the wild
type and mutated channel during the travel of the molecule
from outside to the periplasmic space (Vidal et al., 2005;
James et al., 2009; Hajjar et al., 2010a,b). These data illus-
trates the adaptive pressure that has governed the selection and
the preservation of these speciﬁc residues that ﬁlter the dif-
fusion of charged solutes. The amino acids involved represent
the ﬁrst defense against the penetration of harmful compounds
and support the pioneer investigations reporting the diﬀerence
in β-lactam susceptibility depending on porin (Pagès et al.,
2008).
Recently, in the context of IMI-Translocation consor-
tium (www.translocation.eu), the genomes of various clini-
cal isolates have been sequenced and the preliminary analyses
have reported several mutations in resistant strains that are
located in the regulators and membrane proteins (data not
shown).
Regulation of Membrane-Associated
Mechanisms of Resistance
Various studies on antibiotic resistance in E. aerogenes and E.
cloacae have enlightened on a group of AraC family regulators
including MarA, RamA, SoxS, and RobA, which are associated
with a phenotype of low-level susceptibility to several antibi-
otics and biocides by inducing the overexpression of the eﬄux
pump (for a review see Davin-Regli et al., 2008; Davin-Regli
and Pagès, 2012; Pérez et al., 2012). Interestingly, the role of
marA and ramA has been described also in the downregulation
of porins and the subsequent resistance to β-lactams in E. aero-
genes that completes the MDR phenotype of clinical resistant
strains (Chollet et al., 2002, 2004). Recent work has shown that
the expression of another AraC- regulator, rarA, contribute to
a multidrug-resistance phenotype, generated via the activation
of eﬄux (Veleba et al., 2013). This regulator also has a role in
the development of tigecycline resistance (Veleba et al., 2013).
Thus, the regulation of MDR in Enterobacter is quite complex
and redundant (Davin-Regli et al., 2008; Lawler et al., 2013) and
contributes to the rapid adaptation of the clinical isolate via the
porin and eﬄux balance (Bornet et al., 2000, 2004). Moreover, it
has been demonstrated that some two component system (TCS)
regulators such as OmpR-EnvZ also play a key role in the control
of porin expression in addition to OmpX and the small RNAi or
proteins as H-NS that govern the OmpF/OmpC balance in E. coli
or eﬄux pump elements synthesis in E. aerogenes, respectively
(Stoorvogel et al., 1991; Masi et al., 2005; Dupont et al., 2007).
Interestingly, regarding the genetic control of the pump
expression; activators MarA, RamA, and RarA, and repressors
FIGURE 3 | Schematic illustration of resistance mechanism and their
regulations. Different levels of regulation are presented: (i) Transcriptional and
translational levels controlled by various sensors [two components systems
(TCS), such as EnvZ/OmpR for porins], global regulators (RamA, MarA, SoxS
are indicated here), and local regulators (AcrR for efflux pumps and OmpX for
porins), the accumulation of trigger metabolites inside the bacterial cell can
also trigger the expression via local or other regulators, MicF and MicC
represent the small interfering RNA controlling porin mRNA stability.
(ii) Translational and final membrane assembly in a functional conformation (via
chaperones and membrane factors. Porins represent Omp35, Omp36; Efflux
pumps represent the AcrAB–TolC family. IN, bacterial cytoplasm; OUT,
external medium.
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MarR, RamR, and AcrR, could be intimately associated at a global
and local level to conjointly organize the resistance in clinical
Enterobacter isolates (Davin-Regli et al., 2008). At this moment, it
is also important tomention that the RamA regulator is described
in Enterobacter, Salmonella, and Klebsiella, but not reported in
Escherichia in contrast to the Mar regulon (Lawler et al., 2013).
An illustration of the sophisticated regulation of the various
resistance mechanisms in Enterobacter is presented in Figure 3.
Conclusion
During the last decade, we observed the rise and the fall of sev-
eral infectious episodes due to resistant Escherichia, Enterobacter,
Klebsiella strains in French and European hospitals. Regarding
Enterobacter, we can note the successive waves of E. cloacae,
followed by E. aerogenes and now again E. cloacae reported in
hospital wards (Potron et al., 2013). This bacterial species is a
member of the ESKAPE group recently described as the main
contributor to the health human infection problem (Boucher
et al., 2009; Rice, 2010). Consequently, it is important to exam-
ine the various ways used by E. aerogenes and E. cloacae to detect
and respond to the modiﬁcation of environmental conditions and
the presence of drugs in the medium.
Interestingly, the two Enterobacter species, aerogenes and cloa-
cae, present highly preserved regulation mechanisms acting to
modulate the expression of porins integrated into the outer mem-
brane: for example OmpX the small outer membrane protein,
plays a role in controlling the production of the OmpF-like porin
(Omp35) and OmpX overproduction is reported in clinical iso-
lates showing a porin failure (Stoorvogel et al., 1991; Dupont
et al., 2007). This control of an outer membrane protein (OmpX)
on the synthesis of the outer membrane porin, in addition to
the major regulator of the resistance cascade that are fully active,
are present in various clinical isolates. This suggests a common
evolution path and the selection of a common regulation cas-
cade involved in the membrane adaptation to environmental
stresses (Gayet et al., 2003). About the drug transporters, it is clear
that AcrAB–TolC system, OqxAB, EmrE, MdfA, and MacA are
present in the two species (see data bank for a complete descrip-
tion). In addition, regarding Mar, Ram, and Sox regulators all of
them are preserved and active in the triggering of antibiotic resis-
tance. Interestingly, the redundant global regulatory control, Mar
and Ram, are reported in E. aerogenes andE. cloacae (Veleba et al.,
2013). The close species proximity is reinforced by the presence of
similar regulators and adaptive response and support the descrip-
tion of these species in the human infection and their response
face to antibiotic therapy.
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